Drug Profile
PPL 103
Alternative Names: Opioid derivatives - Phoenix PharmaLabs; PPL-103Latest Information Update: 29 Dec 2022
Price :
$50
*
At a glance
- Originator Phoenix PharmaLabs
- Developer Aoxing Pharmaceutical Company; Phoenix PharmaLabs
- Class Opioid analgesics
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pain; Substance-related disorders
Most Recent Events
- 29 Dec 2022 Preclinical development for substance-related disorders and Pain are underway in USA and China (Phoenix PharmaLabs pipeline, December 2022)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Pain in USA
- 23 Jun 2021 Phoenix PharmaLabs plans phase I, phase II and proof-of-concept trials of PPL 103